| Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight SAW Fuqua, G Gu, Y Rechoum Breast cancer research and treatment 144, 11-19, 2014 | 227 | 2014 |
| AR collaborates with ERα in aromatase inhibitor-resistant breast cancer Y Rechoum, D Rovito, D Iacopetta, I Barone, S Andò, NL Weigel, ... Breast cancer research and treatment 147, 473-485, 2014 | 131 | 2014 |
| ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling L Gelsomino, G Gu, Y Rechoum, AR Beyer, SM Pejerrey, A Tsimelzon, ... Breast cancer research and treatment 157, 253-265, 2016 | 88 | 2016 |
| The role of androgen receptor in breast cancer D Iacopetta, Y Rechoum, SAW Fuqua Drug Discovery Today: Disease Mechanisms 9 (1-2), e19-e27, 2012 | 68 | 2012 |
| Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer A Ciupek, Y Rechoum, G Gu, L Gelsomino, AR Beyer, L Brusco, ... Breast cancer research and treatment 154, 225-237, 2015 | 61 | 2015 |
| The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer SM Pejerrey, D Dustin, JA Kim, G Gu, Y Rechoum, SAW Fuqua Hormones and Cancer 9, 215-228, 2018 | 45 | 2018 |
| Targeting thyroid hormone receptor beta in triple-negative breast cancer G Gu, L Gelsomino, KR Covington, AR Beyer, J Wang, Y Rechoum, ... Breast cancer research and treatment 150, 535-545, 2015 | 43 | 2015 |
| Micro-RNAs: viral genome and robustness of gene expression in the host J Demongeot, E Drouet, A Elena, A Moreira, Y Rechoum, S Sené Philosophical Transactions of the Royal Society A: Mathematical, Physical …, 2009 | 37 | 2009 |
| Hormonal modulation of ESR1 mutant metastasis G Gu, L Tian, SK Herzog, Y Rechoum, L Gelsomino, M Gao, L Du, JA Kim, ... Oncogene 40 (5), 997-1011, 2021 | 26 | 2021 |
| Inhibition of the binding of HCV serum particles to human hepatocytes by E1E2‐specific D32. 10 monoclonal antibody N Ndongo, Y Rechoum, S De Sequeira, F Zoulim, C Trépo, E Drouet, ... Journal of medical virology 81 (10), 1726-1733, 2009 | 11 | 2009 |
| New insights into HCV replication in original cells from Aedes mosquitoes C Fallecker, A Caporossi, Y Rechoum, F Garzoni, S Larrat, O François, ... Virology Journal 14, 1-11, 2017 | 10 | 2017 |
| The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis G Gu, L Tian, M Gao, Y Rechoum, L Gelsomino, D Dustin, ... Cancer Research 78 (13_Supplement), 22-22, 2018 | 5 | 2018 |
| Erratum to: ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling L Gelsomino, G Gu, Y Rechoum, AR Beyer, SM Pejerrey, A Tsimelzon, ... Breast cancer research and treatment 163, 639-640, 2017 | 4 | 2017 |
| ESR1 mutations in cell-free DNA of breast cancer: predictive “tip of the iceberg” SAW Fuqua, Y Rechoum, G Gu JAMA oncology 2 (10), 1315-1316, 2016 | 3 | 2016 |
| PD01-07: AR Overexpression and Aromatase Inhibitor Resistance in Breast Cancer. Y Rechoum, D Iacopetta, I Barone, S Ando’, SF Morales, NL Weigel, ... Cancer Research 71 (24_Supplement), PD01-07-PD01-07, 2011 | 3 | 2011 |
| Abstract S4-02: The Y537S ESR1 mutation is a dominant driver of distant ER-positive breast cancer metastasis SAW Fuqua, G Gu, Y Rechoum, L Gelsomino, DJ Dustin, ... Cancer Research 77 (4_Supplement), S4-02-S4-02, 2017 | 2 | 2017 |
| Collaboration of AR and ERα in conferring resistance to an aromatase inhibitor. Y Rechoum, D Iacopetta, I Barone, D Rovito, S Ando', N Weigel, ... Journal of Clinical Oncology 31 (15_suppl), 579-579, 2013 | 1 | 2013 |
| Method for amplifying hcv in aedes mosquitoes E Drouet, Y Rechoum, F Fouque US Patent App. 12/448,420, 2010 | 1 | 2010 |
| Abstract PD1-07: Mutant ESR1 receptors antagonize the tumor suppressor function of androgen receptors SL Grimm, G Gu, SK Herzog, TL Gonzalez, H Lin, AR Beyer, Y Rechoum, ... Cancer Research 82 (4_Supplement), PD1-07-PD1-07, 2022 | | 2022 |
| Hormonal modulation of ESR1 mutant metastasis (vol 40, pg 997, 2021) G Gu, L Tian, SK Herzog, Y Rechoum, L Gelsomino, M Gao, L Du, JA Kim, ... ONCOGENE 41 (3), 460-460, 2022 | | 2022 |
